evelo biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. these new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. by finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, evelo can improve the speed, cost and success of drug discovery and development. evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. evelo biosciences was conceived and created within venturelabs®, flag
Company profile
Ticker
EVLO
Exchange
Website
CEO
Balkrishan Gill
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Evelo Biosciences (UK) Limited • Evelo Biosciences Security Corporation ...
EVLO stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
11 Mar 24
15-12G
Securities registration termination
26 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 24
POS AM
Prospectus update (post-effective amendment)
26 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
26 Jan 24
25-NSE
Exchange delisting
27 Dec 23
DEFA14A
Additional proxy soliciting materials
12 Dec 23
DEF 14A
Definitive proxy
12 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4 Dec 23
Transcripts
EVLO
Earnings call transcript
2022 Q4
16 Mar 23
EVLO
Earnings call transcript
2022 Q2
12 Aug 22
EVLO
Earnings call transcript
2021 Q4
24 Mar 22
EVLO
Earnings call transcript
2021 Q3
28 Oct 21
EVLO
Earnings call transcript
2021 Q2
1 Aug 21
EVLO
Earnings call transcript
2021 Q2
29 Jul 21
EVLO
Earnings call transcript
2021 Q1
1 May 21
EVLO
Earnings call transcript
2020 Q4
9 Mar 21
EVLO
Earnings call transcript
2020 Q3
1 Nov 20
EVLO
Earnings call transcript
2020 Q3
29 Oct 20
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 18.06 mm | 18.06 mm | 18.06 mm | 18.06 mm | 18.06 mm | 18.06 mm |
Cash burn (monthly) | (no burn) | 4.35 mm | 4.13 mm | 6.79 mm | 3.47 mm | 6.14 mm |
Cash used (since last report) | n/a | 25.97 mm | 24.66 mm | 40.55 mm | 20.73 mm | 36.70 mm |
Cash remaining | n/a | -7.91 mm | -6.60 mm | -22.50 mm | -2.67 mm | -18.64 mm |
Runway (months of cash) | n/a | -1.8 | -1.6 | -3.3 | -0.8 | -3.0 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 26 |
Opened positions | 1 |
Closed positions | 15 |
Increased positions | 2 |
Reduced positions | 21 |
13F shares | Current |
---|---|
Total value | 10.96 bn |
Total shares | 22.99 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Flagship Ventures Fund V | 16.34 mm | $34.65 mm |
HarbourVest Partners | 3.06 mm | $0.00 |
Flagship Pioneering | 2.52 mm | $8.19 bn |
State Of Michigan Retirement System | 203.54 k | $661.49 mm |
Credit Suisse | 180.52 k | $180.52 mm |
Vanguard | 155.90 k | $506.66 mm |
Harbourvest Partners | 153.18 k | $497.82 mm |
FMR | 126.43 k | $410.88 mm |
BCS Barclays | 93.19 k | $303.00 k |
BLK Blackrock | 53.54 k | $174.00 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Nov 23 | Mark Bodmer | Common Stock | Sell | Dispose S | No | Yes | 0.33 | 3,163 | 1.04 k | 25,732 |
8 Nov 23 | Simba Gill | Common Stock | Sell | Dispose S | No | Yes | 0.33 | 172 | 56.76 | 17,758 |
8 Nov 23 | Marella Thorell | Common Stock | Sell | Dispose S | No | Yes | 0.33 | 1,811 | 597.63 | 22,259 |
8 Nov 23 | Duncan McHale | Common Stock | Sell | Dispose S | No | Yes | 0.33 | 3,103 | 1.02 k | 16,984 |
7 Nov 23 | Mark Bodmer | Common Stock | Option exercise | Acquire M | No | No | 0 | 6,625 | 0.00 | 28,895 |
7 Nov 23 | Mark Bodmer | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 6,625 | 0.00 | 6,625 |
7 Nov 23 | Simba Gill | Common Stock | Option exercise | Acquire M | No | No | 0 | 1,172 | 0.00 | 17,930 |
7 Nov 23 | Simba Gill | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 1,172 | 0.00 | 15,236 |
7 Nov 23 | Marella Thorell | Common Stock | Option exercise | Acquire M | No | No | 0 | 6,500 | 0.00 | 24,070 |
7 Nov 23 | Marella Thorell | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 6,500 | 0.00 | 6,500 |